Company Overview and News

 
Marksans Pharma Limited - Reply to Clarification Sought

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
524404 MARKSANS

 
Marksans Pharma Limited - Clarification

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
524404 MARKSANS

 
Marksans Pharma Limited - AGM/Book Closure

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
524404 MARKSANS

3
JSW Steel hits 52-week high, Lupin falls 2% after NSE announces rejig of Nifty

2018-08-29 moneycontrol
Shares of Lupin down 2 percent, while JSW Steel touched 52-week high of Rs 379.50, rising more than 3 percent after National Stock Exchange (NSE) announced fresh Nifty rejig effective from September 28.
PWQFY KESORAMIND 500228 BHUSANSTL 533096 532418 532955 MARKSANS 533155 532810 JUBLFOOD ABAN CMQMY 532461 ENGINERSIN JBLWY 532480 CUMMINSIND 500055 502937 524404 ALNSE ALBK JSWSTEEL 532401 VIJAYABANK BRK.A PFC 532178 500480 PNJZY PNB 534809 ADANIPOWER PCJEWELLER RECLTD 523204 KRIDF ANDHRABANK

 
Marksans Pharma Limited - Shareholders meeting

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
524404 MARKSANS

4
D-Street Buzz: Nifty Pharma outperforms led by Dr Reddy#39;s Labs; MGL most active, falls 6%, Prataap Snacks zooms 17%

2018-08-23 moneycontrol
The Indian benchmark indices are trading on a positive note this Thursday morning with the Nifty up 17 points and trading at 11,588. The Sensex on the other hand is up 71 points and is trading at 38,356.
500825 AMKD ADANIENT AUROPHARMA BRTQY 532715 AMTEKAUTO 532218 MARKSANS 532899 BHRQY 512599 532215 GITANJALI SOUTHBANK 532343 MOZTY AXISBANK KSCL 500570 BHARTIARTL BRITANNIA TATAMOTORS 524404 517354 ANNRY HVLQY TVSMOTOR AXB 524804 517334 AXBKY 532454 GTJLY AXBA BATAINDIA MOTHERSUMI ARBQY HAVELLS 520077 500043 TTM

 
Marksans Pharma shares jump 15% after healthy profit growth in June quarter

2018-08-06 moneycontrol
Marksans Pharma share price rallied 14.55 percent intraday Monday after the company reported healthy profit growth for the quarter ended June 2018.
524404 MARKSANS

 
Marksans Pharma Limited - Financial Result Updates

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
524404 MARKSANS

 
Marksans Pharma Limited - Press Release

2018-08-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
524404 MARKSANS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...